@article{article, keywords = {Chagas Cardiomyopathy, Chagas disease, Heart Failure, Sacubitril/valsartan}, author = {Abramov D and Minhas A and Alexy T and Guimaraes P and Lainscak M and Myhre P}, title = {Evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas{\textquoteright} disease}, abstract = {
Heart failure is a common manifestation of Chagas{\textquoteright} disease and results in significant morbidity and mortality in affected patients. In light of limited data on therapeutic options for heart failure due to Chagas{\textquoteright} disease, the PARACHUTE-HF trial aimed to compare the effects of sacubitril/valsartan versus enalapril on clinical endpoints and changes in natriuretic peptides in this population. This mini-review contextualizes the results of the trial, which demonstrated that sacubitril/valsartan led to significant improvements in outcomes driven primarily by a reduction in natriuretic peptides.
}, year = {2026}, journal = {Heart failure reviews}, volume = {31}, pages = {1 - 4}, month = {03/2026}, issn = {1573-7322}, url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13035569/pdf/10741_2026_Article_10617.pdf}, doi = {10.1007/s10741-026-10617-3}, language = {ENG}, }